Drug firms' collaboration pools HIV treatments
Tuesday 03 November 2009
ViiV Healthcare, an unusual collaboration between GlaxoSmithKline and Pfizer, two of the world’s biggest drugs companies, was launched today with a mandate to pool the two firms’ HIV treatments.
ViiV will inherit GSK’s agEing portfolio of HIV medicines, including Combivir, which will lose its patent protection in three year’s time, and Pfizer’s younger and largely untested drugs, such as Selzentry, which ViiV’s chief executive Dominique Limet today described as the company’s “key driver and lever for growth.” Dr Limet takes the helm at ViiV after stepping down as GSK’s head of personalised medicines.
GSK, which is contributing 90 per cent of the £250m start-up costs, will be the major shareholder with an initial 85 per cent of the equity. This also reflects the UK company’s bigger portfolio of marketed drugs, which will initially contribute the most of the new group's revenues.
The equity split will change, however, depending on which company’s medicines and molecules contribute most to profits in the future. The US group has a stronger line of less well developed HIV treatments and will capture a bigger slice of the equity, as much as 30.5 per cent, if its pipeline treatments successfully negotiate clinical trials.
ViiV has 11 marketed medicines and seven molecules in its portfolio.
A number of pharmaceutical groups, including the Swiss giant Roche, have withdrawn from the HIV drug market, blaming increasing difficult commercial conditions.
Dr Limet acknowledged that the market for HIV was challenging: “In truth, we have to get closer to those people who live with the virus,” he said. “Much of our historic effort has been led by the virus – a chase of science. This must continue, but we must also listen and better understand the needs of people living with HIV.”
ViiV has pro forma sales of £1.6bn last year, giving it a 19 per cent market share, behind US group Gilead’s 31 per cent share.
The establishment of ViiV, which was first announced in April, follows GSK’s strategy of concentrating in niche areas, and avoiding costly blockbuster drug research. At the time of the initial announcement GSK’s chief executive Andrew Witty said the deal help the group to guard against the loss of the revenues it will suffer over the next few years as its leading HIV treatments, including Combivir, lose patent protection and are open to competition from generic drug makers.
- 1 Autism 'caused by genetics', study suggests
- 2 What happens to your body when you give up sugar?
- 3 Why you should never make assumptions about people with autism
- 4 Tourist films plane's descent just metres above packed Caribbean beach
- 5 Have sex with your iPad thanks to the new sex toy no-one asked for
Tourist films plane's descent just metres above packed Caribbean beach
Bali nine: Welcome to 'Execution Island' – the Indonesian holiday resort where foreigners are sent to die
How Homer Simpson discovered the Higgs boson over a decade before scientists
The 'sex selfie stick' lets you FaceTime the inside of a vagina
Harrison Ford plane crash: Star Wars actor 'seriously injured' after light aircraft crash lands
Durham Free School: 'Creationism taught at' free school facing closure
Nearly 100,000 of Britain's poorest children go hungry after parents' benefits are cut
End of the licence fee: BBC to back radical overhaul of how it is funded
Ex-head of MI6: 'We shouldn't kid ourselves that Russia is on a path to democracy'
Most people think legal tax avoidance is just as wrong as illegal tax evasion, poll suggests
Nigel Farage promises Ukip will not 'stigmatise' would-be migrants – and says he wants 'everyone to speak the same language'
iJobs Money & Business
£13000 per annum: Recruitment Genius: This is an exciting opportunity to join ...
£25000 - £30000 per annum + benefits: Ashdown Group: A global leader operating...
£8 per hour: Recruitment Genius: This Pension Specialist was established early...
£30 - 35k + Bonus & Benefits: Guru Careers: We are seeking an Executive Assist...